|
May 12, 2026
|
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
|
|
|
May 12, 2026
|
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
|
|
|
April 23, 2026
|
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
|
|
|
March 31, 2026
|
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
|
|
|
March 30, 2026
|
Connect Biopharma Announces $20.2 Million Private Placement Financing
|
|
|
March 30, 2026
|
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
|
|
|
March 30, 2026
|
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
|
|
|
March 10, 2026
|
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
|
|
|
March 3, 2026
|
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
|
|
|
February 19, 2026
|
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
|
|
